Protective effect of resveratrol against nigrostriatal pathway injury in striatum via JNK pathway

Brain Res. 2017 Jan 1;1654(Pt A):1-8. doi: 10.1016/j.brainres.2016.10.013. Epub 2016 Oct 18.

Abstract

Nigrostriatal pathway injury is one of the traumatic brain injury models that usually lead to neurological dysfunction or neuron necrosis. Resveratrol-induced benefits have recently been demonstrated in several models of neuronal degeneration diseases. However, the protective properties of resveratrol against neurodegeneration have not been explored definitely. Thus, we employ the nigrostriatal pathway injury model to mimic the insults on the brain. Resveratrol decreased the p-ERK expression and increased the p-JNK expression compared to the DMSO group, but not alter the p38 MAPK proteins around the lesion site by Western blot. Prior to the injury, mice were infused with resveratrol intracerebroventricularly with or without JNK-IN-8, a specific c-JNK pathway inhibitor for JNK1, JNK2 and JNK4. The study assessed modified improved neurological function score (mNSS) and beam/walking test, the level of inflammatory cytokines IL-1β, IL-6 and TNF-α, and striatal expression of Bax and Bcl-2 proteins associated with neuronal apoptosis. The results revealed that resveratrol exerted a neuroprotective effect as shown by the improved mNSS and beam latency, anti-inflammatory effects as indicated by the decreased level of IL-1β, TNF-α and IL-6. Furthermore, resveratrol up-regulated the protein expression of p-JNK and Bcl-2, down-regulated the expression of Bax and the number of Fluoro-Jade C (FJC) positive neurons. However, these advantages of resveratrol were abolished by JNK-IN-8 treatment. Overall, we demonstrated that resveratrol treatment attenuates the nigrostriatal pathway injury-induced neuronal apoptosis and inflammation via activation of c-JNK signaling.

Keywords: Apoptosis; Inflammation; JNK pathway; Nigrostriatal pathway injury; Resveratrol.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Apoptosis / physiology
  • Brain Injuries, Traumatic / complications
  • Brain Injuries, Traumatic / drug therapy*
  • Brain Injuries, Traumatic / enzymology
  • Brain Injuries, Traumatic / pathology
  • Corpus Striatum / drug effects*
  • Corpus Striatum / enzymology
  • Corpus Striatum / injuries
  • Corpus Striatum / pathology
  • Disease Models, Animal
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • MAP Kinase Kinase 4 / antagonists & inhibitors
  • MAP Kinase Kinase 4 / metabolism*
  • MAP Kinase Signaling System / drug effects
  • Male
  • Mice
  • Neural Pathways / drug effects
  • Neural Pathways / enzymology
  • Neural Pathways / injuries
  • Neural Pathways / pathology
  • Neurodegenerative Diseases / drug therapy
  • Neurodegenerative Diseases / enzymology
  • Neurodegenerative Diseases / etiology
  • Neurodegenerative Diseases / pathology
  • Neurons / drug effects
  • Neurons / enzymology
  • Neurons / pathology
  • Neuroprotective Agents / pharmacology*
  • Phosphorylation
  • Random Allocation
  • Resveratrol
  • Stilbenes / pharmacology*
  • Substantia Nigra / drug effects*
  • Substantia Nigra / enzymology
  • Substantia Nigra / injuries
  • Substantia Nigra / pathology
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Neuroprotective Agents
  • Stilbenes
  • Extracellular Signal-Regulated MAP Kinases
  • p38 Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase 4
  • Resveratrol